CapForce Inc. · OTC:CFOR
CapForce — Opgen — Investor Presentation (November 2016)
29 slides from CapForce's investor presentation, Nov 16, 2016
Slide 1: Corporate Presentation November 2016
CORPORATE PRESENTATION November 2016
Slide 2: Forward-looking statements
This presentation includes statements relating to the company's Acuitas® MDRO, Acuitas Lighthouse® and QuickFISH® products and services, and commercialization plans for these products and services. These statements and other statements regarding our future plans and goals constitute "forward-looking
Slide 3: Uniquely positioned to address rising antibiotic resistance crisis
Uniquely positioned to address rising antibiotic resistance crisis •Leader in leveraging genomics and informatics for infectious disease •Significant global challenge and market opportunity •Equating to a >$2 billion market in need of a solution to the infectious disease crisis and associated health
Slide 4: Antibiotic Resistance — A Building Crisis
Antibiotic Resistance — A Building Crisis National Action Plan for Combating Antibiotic-Resistant Bacteria supports $1B+ federal investments to combat drug resistant infections with rapid diagnostics, surveillance and accelerated discovery and development of new antibiotics 2 Lt) 2050: A BIGGER KILL
Slide 5: Significant Financial Toll on Hospitals and Healthcare System
Significant Financial Toll on Hospitals and Healthcare System Direct Costs * Increased length of stay * Drug costs * CMS financial penalties Indirect Costs ¢ Mortality risk * Resistance and C. diff rise ¢ Risk of infection spreading 2OpGen internal data
Slide 6: Revolutionary Approach to Antibiotic Decision Making
Revolutionary Approach to Antibiotic Decision Making Current: 2-6 days Empiric Pathogen antibiotic identification re: « - , ° | OpGen Solution i _» Kgenyo ‘ “e a te Mowe ------------- > — an a 2. in Hours’ =e i Pathogen Lighthouse Right Knowledgebase Antibiotic f@OpGen" +In development
Slide 7: OpGen Solution: Genomic Knowledgebase of Drug-Resistant Pathogens
OpGen Solution: Genomic Knowledgebase of Drug-Resistant Pathogens Thousands of pathogens from hospitals worldwide J@OpGen’ B Drug susceptibility testing Genomic analysis, DNA sequencing Patient hospital data wan ©. ” Lighthouse Knowledge Database fa Healthcare a4 management <p information Insights t
Slide 8: Sample Workflow and Report
Sample Workflow and Report 3 © 1-3 hour test Acuitas® Lighthouse cloud-based query* Lab report with antibiotic-specific guidance Send sample to lab Bedside sample collection f@OpGen’ +In development Acuitas mAST™ Antibiotic Lighth Profil (e] it ighthouse Profile rganism Resisatee Genes K1:KPC1_SHV4_
Slide 9: Lighthouse Revenue Streams
Lighthouse Revenue Streams Data/Revenue Streams Analytics and interfaces providing vast amounts of data Acuitas Rapid mAST Test $2 Blood Ur Respiratory Billion® Lighthouse Knowledgebase Hospital MDRO surveillance stewardship software mes stud inical trials Every data stream adds to the Lighthouse Kn
Slide 10: External Validation Drivers
External Validation Drivers © GLOBAL HEALTH _.. INNOVATION S\/Z Intermountain’ Healthcare BCHA Hospital Association f@OpGen" 10
Slide 11: Integrated HMO retrospective study
•Leading integrated HMO retrospective study •Costs projected to double •Potential savings from rapid antibiotic decision-making •Results support multiple data/revenue streams
Slide 12: Rapid Complicated Urinary Tract Infection Management
Rapid Complicated Urinary Tract Infection Management OpGen — <3 Hours* Current — 2+ Days Culture + MALDI + AST Ol ID AST 1.5 million U.S. patients at risk 300 thousand cUTI cases annually F@OPGEN evenen 12
Slide 13: Blood Stream Infection Patient Management
Blood Stream Infection Patient Management OpGen — 1-4 Hours Post Blood Culture; Future: 4 Hours Direct from Blood Current — 2-3 Days Culture + MALDI + AST More than a million U.S. patients with severe sepsis annually® An estimated 28-50% of these people die — far more than the number of U.S. deaths
Slide 14: Hospital ICU MDRO Management
Hospital ICU MDRO Management Transplant, Oncology, High-Acuity ICUs, Pre-surgical Admissions OpGen CLIA Complete MDRO Solution Current VRE, MRSA Screening Successful Pilots: HARP-DC, 16 Hospitals Intermountain Healthcare, Utah Culture + MALDI + AST f@OpGen" Molecular Profile mAST Data 14
Slide 15: HARP-DC MDRO Surveillance Study
•HARP-DC MDRO Surveillance Study •Nation’s capital leads in proactively addressing MDROs in communities and health facilities •Acuitas solution deployed in 16 D.C. health care facilities during the course of the study
Slide 16: Lighthouse reporting and analytics platform
Individual hospital and patient reporting with geospatial analysis Advanced analytics engine Direct connection to LIMS database Cloud-based HIPAA compliantSecurity •End-to-end encryption (database, connectors, browser SSL) •Federated access permissions
Slide 17: Merck Global Health Innovation Fund investment
•Merck Global Health Investment Fund invests where Merck’s expertise can help accelerate revenue growth and enhance value creation •$10.5 million investment •November 2016: Research collaboration with Merck to develop novel rapid diagnostics and informatics tools to combat antibiotic resistance •Acc
Slide 18: Product Development Momentum
Product Development Momentum Today Automation of current DNA tests Research Lighthouse Pathogen/Drug Profile Data Improving Data Content & User Interface f@OpGen Clinical Studies 18
Slide 19: Acuitas mAST Development Path
Acuitas mAST Development Path Genomic Discovery Engine CLIA Lab for microbial sequence/antibiotic phenotype analysis forgets Commercial Custom genotyping & DNA sequencing tests Complete/Commercial Verification of test performance Complete Test thousands of pathogens Underway Lighthouse Data Warehous
Slide 20: Large Rapid Antibiotic Decision-Making Markets
Large Rapid Antibiotic Decision-Making Markets $2B Global Market Global Hospital Acquired Infection $22 Testing Revenue 2012 19% CAGR: One of the fastest growing U.S. molecular diagnostic segments L ipigtg! gt o iy Multiple high-acuity ] patient types = een | Total® Urinary Tract Surgical Site Pneum
Slide 21: Competitive Landscape
Competitive Landscape f@OpGen" Rapid Phenotypic AST Accelerate Diagnostics, GeneWeave/Roche Rapid Molecular Cepheid, BioFire/bioMérieux, Luminex/Nanosphere f@OpGen’ ‘In development Complete Antibiotic Resistance Decision Making Solution* Current & new antibiotics High resolution genetics Global Ligh
Slide 22: Acuitas mAST Commercial Strategy
Acuitas mAST Commercial Strategy mAST economics: >500 bed hospital 5-10 tests per day + ~3,000 tests per year + $150-$200 ASP {. Estimated $500 million annual U.S. revenue opportunity" f@OpGen" 11 Assumes 1,000 hospitals with 2500 beds Key commercialization milestones 2017: Commercialize ASR/LDT in
Slide 23: Strategy for Growth
Strategy for Growth Building Total Infectious Disease Solutions for Hospitals & Health Systems Pharma ntracts 100+ Hospital Accounts ded Dis Co-marketing Relationships Acquisition of New Products New Product Launches f@OpGen" 23
Slide 24: Building on First Mover Advantage
Building on First Mover Advantage Merck HARP-DC — 16 Intermountain Galles Target for 1st GHI Health Care Healthcare Coe mAST Investment Knowledgebase Diagnostics Facility Retrospective Agreement Citywide Study Study Rapid Automated Target for Pathogen mAST FDA. Submission Acuitas theron Rees Merck S
Slide 25: Financial highlights: nine months ended September 30, 2016
•Nine months ended September 30, 2016 •$3.0 million total revenue - up 65% from 2015 ($1.8 million) •$2.7 million product revenue – up 90% from 2015 ($1.5 million) •53% gross margin on product sales •Q3 ended September 30, 2016 •$760 thousand total revenue – down 23% from 2015 (1.0 million) •$730 th
Slide 26: Experienced Management Team
Experienced Management Team Evan Jones EXDIGENE FOUNDATION Fe FLUIDIGM Wveracyte Chairman & Chief Executive Officer Timothy Dec FORTRESS << ThermoFisher Chief Financial Officer pomwanel i ni corvis SCIENTIFIC Robert McG. Lilley Chief Commercial Officer EXDIGENE ANUTEL Chief Information Officer een r
Slide 27: Near-Term Milestones
Near-Term Milestones Q4 16 IHC Health Outcomes Study 11 Pharma information agreement 17 MAST performance verification Health system information services 241 Automated rapid pathogen ID FDA submission Automated pathogen ID launch MAST clinical trials and ASR/LDT Third party development funding f@OpGe
Slide 28: Uniquely positioned to address rising antibiotic resistance crisis
Uniquely positioned to address rising antibiotic resistance crisis •Leader in leveraging genomics and informatics for infectious disease •Significant global challenge and market opportunity •Equating to a >$2 billion market in need of a solution to the infectious disease crisis and associated health
Slide 29: Thank You
fq OpGen’ CORPORATE PRESENTATION Thank You